VERA Valuation

Vera Therapeutics Inc

Add to Watchlist

Advanced Chart

26.340

+1.8(7.335%)1D

Overview
Forecast
Valuation
Earnings

VERA Relative Valuation

VERA's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average, adjusted by weights. If the market price exceeds this fair value range, VERA is overvalued; if below, it's undervalued.

Historical Valuation

Vera Therapeutics Inc (VERA) is now in the Fair zone, suggesting that its current forward PS ratio of 0.00 is considered Fairly compared with the five-year average of -7.91. The fair price of Vera Therapeutics Inc (VERA) is between to according to relative valuation methord.

Relative Value

Fair Zone

Current Price：25.10

Fair

-4.79

Trailing

Forward

-3.82

EV/EBITDA

Vera Therapeutics Inc. (VERA) has a current EV/EBITDA of -3.82. The 5-year average EV/EBITDA is -5.03. The thresholds are as follows: Strongly Undervalued below -14.31, Undervalued between -14.31 and -9.67, Fairly Valued between -0.40 and -9.67, Overvalued between -0.40 and 4.24, and Strongly Overvalued above 4.24. The current Forward EV/EBITDA of -3.82 falls within the Historic Trend Line -Fairly Valued range.

-3.32

EV/EBIT

Vera Therapeutics Inc. (VERA) has a current EV/EBIT of -3.32. The 5-year average EV/EBIT is -6.51. The thresholds are as follows: Strongly Undervalued below -14.55, Undervalued between -14.55 and -10.53, Fairly Valued between -2.49 and -10.53, Overvalued between -2.49 and 1.52, and Strongly Overvalued above 1.52. The current Forward EV/EBIT of -3.32 falls within the Historic Trend Line -Fairly Valued range.

0.00

Vera Therapeutics Inc. (VERA) has a current PS of 0.00. The 5-year average PS is 4.71. The thresholds are as follows: Strongly Undervalued below -58.00, Undervalued between -58.00 and -26.64, Fairly Valued between 36.07 and -26.64, Overvalued between 36.07 and 67.42, and Strongly Overvalued above 67.42. The current Forward PS of 0.00 falls within the Historic Trend Line -Fairly Valued range.

-4.81

P/OCF

Vera Therapeutics Inc. (VERA) has a current P/OCF of -4.81. The 5-year average P/OCF is -8.74. The thresholds are as follows: Strongly Undervalued below -19.69, Undervalued between -19.69 and -14.21, Fairly Valued between -3.27 and -14.21, Overvalued between -3.27 and 2.20, and Strongly Overvalued above 2.20. The current Forward P/OCF of -4.81 falls within the Historic Trend Line -Fairly Valued range.

-5.42

P/FCF

Vera Therapeutics Inc. (VERA) has a current P/FCF of -5.42. The 5-year average P/FCF is -10.86. The thresholds are as follows: Strongly Undervalued below -22.27, Undervalued between -22.27 and -16.56, Fairly Valued between -5.15 and -16.56, Overvalued between -5.15 and 0.56, and Strongly Overvalued above 0.56. The current Forward P/FCF of -5.42 falls within the Historic Trend Line -Fairly Valued range.

Vera Therapeutics Inc (VERA) has a current Price-to-Book (P/B) ratio of 3.34. Compared to its 3-year average P/B ratio of 5.59 , the current P/B ratio is approximately -40.20% higher. Relative to its 5-year average P/B ratio of 5.19, the current P/B ratio is about -35.57% higher. Vera Therapeutics Inc (VERA) has a Forward Free Cash Flow (FCF) yield of approximately -11.80%. Compared to its 3-year average FCF yield of -11.35%, the current FCF yield is approximately 3.97% lower. Relative to its 5-year average FCF yield of -10.46% , the current FCF yield is about 12.91% lower.

3.34

P/B

Median3y

5.59

Median5y

5.19

-11.80

FCF Yield

Median3y

-11.35

Median5y

-10.46

Competitors Valuation Multiple

The average P/S ratio for VERA's competitors is 137.55, providing a benchmark for relative valuation. Vera Therapeutics Inc Corp (VERA) exhibits a P/S ratio of 0.00, which is -100.00% above the industry average. Given its robust revenue growth of %, this premium appears unsustainable.

P/S

P/E

EV/EBITDA

EV/EBIT

P/S

Revenue Growth

Market Cap

VERA.O

Vera Therapeutics Inc

Twist Bioscience Corp

Edgewise Therapeutics Inc

Janux Therapeutics Inc

Celldex Therapeutics Inc

391.10

-70.78%

1.62B

Performance Decomposition

Market capitalization of VERA increased by 0.00% over the past 1 year. The primary factor behind the change was an decrease in Unknown from 0.00 to 0.00.

The secondary factor is the Unknown, contributed 0.00%to the performance.

Overall, the performance of VERA in the past 1 year is driven by Unknown.